Two Phase 3 trials, BRUIN CLL-313 and BRUIN CLL-314, reported results on pirtobrutinib in first-line chronic lymphocytic leukemia, tightening the field around how sequencing may evolve. While hematologists highlighted the strength of the dataset, experts urged caution on how the new evidence should be placed relative to existing covalent and noncovalent strategies.